Literature DB >> 20388697

Sensitivity to temozolomide in brain tumor initiating cells.

Michael D Blough1, Morgan R Westgate, Desiree Beauchamp, John J Kelly, Owen Stechishin, Andrea L Ramirez, Samuel Weiss, J Gregory Cairncross.   

Abstract

Molecular alterations in glioblastoma have the potential to guide treatment. Here, we explore the relationship between temozolomide (TMZ) response and O(6)-methylguanine DNA methyltransferase (MGMT) status in brain tumor initiating cells (BTICs). Methylation, expression, and sensitivity were assessed in 20 lines; associations were evaluated by Fisher's exact test. Some BTICs were sensitive. Sensitivity to TMZ was only associated with protein expression (P = .001). There were atypical BTICs including TMZ-resistant lines in which the methylation-specific PCR reaction revealed both methylated and unmethylated bands. BTICs are not uniformly resistant to TMZ; some are sensitive. MGMT status does not predict TMZ response with high precision.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20388697      PMCID： PMC2940656          DOI： 10.1093/neuonc/noq032

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


  19 in total

1.  Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system.

Authors:  B A Reynolds; S Weiss
Journal:  Science       Date:  1992-03-27       Impact factor: 47.728

Review 2.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

3.  Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype.

Authors:  Andrea Salmaggi; Amerigo Boiardi; Maurizio Gelati; Annamaria Russo; Chiara Calatozzolo; Emilio Ciusani; Francesca Luisa Sciacca; Arianna Ottolina; Eugenio Agostino Parati; Caterina La Porta; Giulio Alessandri; Carlo Marras; Danilo Croci; Marco De Rossi
Journal:  Glia       Date:  2006-12       Impact factor: 7.452

4.  Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene.

Authors:  X C Qian; T P Brent
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

5.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Repair of alkylated DNA in Escherichia coli. Methyl group transfer from O6-methylguanine to a protein cysteine residue.

Authors:  M Olsson; T Lindahl
Journal:  J Biol Chem       Date:  1980-11-25       Impact factor: 5.157

9.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.

Authors:  John J P Kelly; Owen Stechishin; Andrew Chojnacki; Xueqing Lun; Beichen Sun; Donna L Senger; Peter Forsyth; Roland N Auer; Jeff F Dunn; J Gregory Cairncross; Ian F Parney; Samuel Weiss
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277
View more
  34 in total

Review 1.  Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies.

Authors:  Atique U Ahmed; Brenda Auffinger; Maciej S Lesniak
Journal:  Expert Rev Neurother       Date:  2013-05       Impact factor: 4.618

Review 2.  The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.

Authors:  Brenda Auffinger; Drew Spencer; Peter Pytel; Atique U Ahmed; Maciej S Lesniak
Journal:  Expert Rev Neurother       Date:  2015-05-31       Impact factor: 4.618

3.  Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.

Authors:  Dagmar Beier; Beate Schriefer; Konstantin Brawanski; Peter Hau; Joachim Weis; Jörg B Schulz; Christoph P Beier
Journal:  J Neurooncol       Date:  2012-04-29       Impact factor: 4.130

4.  Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

Authors:  Ryuichi Kanai; Samuel D Rabkin; Stephen Yip; Donatella Sgubin; Cecile M Zaupa; Yuichi Hirose; David N Louis; Hiroaki Wakimoto; Robert L Martuza
Journal:  J Natl Cancer Inst       Date:  2011-12-15       Impact factor: 13.506

5.  Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.

Authors:  Daniela Meco; Tiziana Servidei; Giuseppe Lamorte; Elena Binda; Vincenzo Arena; Riccardo Riccardi
Journal:  Neuro Oncol       Date:  2014-02-12       Impact factor: 12.300

6.  Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.

Authors:  Nusrat Jahan; Jae M Lee; Khalid Shah; Hiroaki Wakimoto
Journal:  Int J Cancer       Date:  2017-07-19       Impact factor: 7.396

7.  Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Authors:  Franz J Zemp; Xueqing Lun; Brienne A McKenzie; Hongyuan Zhou; Lori Maxwell; Beichen Sun; John J P Kelly; Owen Stechishin; Artee Luchman; Samuel Weiss; J Gregory Cairncross; Mark G Hamilton; Brian A Rabinovich; Masmudur M Rahman; Mohamed R Mohamed; Sherin Smallwood; Donna L Senger; John Bell; Grant McFadden; Peter A Forsyth
Journal:  Neuro Oncol       Date:  2013-04-12       Impact factor: 12.300

8.  Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells.

Authors:  Smile Echizenya; Yukiko Ishii; Satoshi Kitazawa; Tadashi Tanaka; Shun Matsuda; Eriko Watanabe; Masao Umekawa; Shunsuke Terasaka; Kiyohiro Houkin; Tomohisa Hatta; Tohru Natsume; Yoshimasa Maeda; Shin-Ichi Watanabe; Shinji Hagiwara; Toru Kondo
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

9.  On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

Authors:  Owen D Stechishin; H Artee Luchman; Yibing Ruan; Michael D Blough; Stephanie A Nguyen; John J Kelly; J Gregory Cairncross; Samuel Weiss
Journal:  Neuro Oncol       Date:  2012-12-21       Impact factor: 12.300

10.  Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.

Authors:  Brad Davis; Yaoqing Shen; Candice C Poon; H Artee Luchman; Owen D Stechishin; Carly S Pontifex; Wei Wu; John J Kelly; Michael D Blough
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.